ProPhase Labs, Inc.
General ticker "PRPH" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $8.6M (TTM average)
ProPhase Labs, Inc. does not follow the US Stock Market performance with the rate: -24.5%.
Estimated limits based on current volatility of 3.4%: low 0.02$, high 0.02$
Factors to consider:
- Total employees count: 96 as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Inability to raise capital, Regulatory and compliance, Product development failure, Cybersecurity threats, Labor/talent shortage/retention
- Current price 97.3% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.75$, 2.41$]
- 2026-12-31 to 2027-12-31 estimated range: [0.73$, 2.19$]
Financial Metrics affecting the PRPH estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -165.98 <= 0.28
- Positive: Return on assets ratio (scaled to [-100,100]) of 28.09 > 6.06
- Positive: Investing cash flow per share per price, % of 18.30 > -0.64
- Positive: Inventory ratio change, % of -17.20 <= -0.75
- Positive: Shareholder equity ratio, % of 5.86 <= 18.97
Short-term PRPH quotes
Long-term PRPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $44.38MM | $6.77MM | $4.34MM |
| Operating Expenses | $65.60MM | $45.40MM | $22.39MM |
| Operating Income | $-21.22MM | $-38.63MM | $-18.05MM |
| Non-Operating Income | $-1.18MM | $-3.70MM | $-5.34MM |
| Interest Expense | $1.27MM | $3.35MM | $6.93MM |
| R&D Expense | $1.40MM | $0.59MM | $0.11MM |
| Income(Loss) | $-22.40MM | $-42.33MM | $-23.39MM |
| Taxes | $-6.02MM | $7.20MM | $-0.00MM |
| Other Income(Loss) | $-0.40MM | $-3.84MM | $0.00MM |
| Net Income(Loss)* | $-16.78MM | $-53.36MM | $-14.74MM |
| Stockholders Equity | $49.38MM | $7.35MM | $3.51MM |
| Inventory | $2.29MM | $1.14MM | $0.07MM |
| Assets | $91.93MM | $63.20MM | $59.87MM |
| Operating Cash Flow | $-11.89MM | $-17.54MM | $-8.34MM |
| Capital expenditure | $3.15MM | $0.91MM | $0.00MM |
| Investing Cash Flow | $-1.37MM | $2.42MM | $0.92MM |
| Financing Cash Flow | $5.76MM | $14.19MM | $6.84MM |
| Earnings Per Share** | $-9.75 | $-27.97 | $-1.74 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.